MODERN VIEWS ON THE USE OF DORIPENEM IN CLINICAL PRACTICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The ubiquitous appearance and rapid spread of nosocomial gram-negative pathogens with multiple resistance to antimicrobial agents is an extremely alarming trend throughout the world. In this regard, health care systems of all countries face an issue of most efficient use of available antibacterial drugs in hospitals, and first of all it concerns carbapenems. The article presents information on the comparative antimicrobial activity of imipenem, meropenem and doripenem in relation to problem Gram-negative pathogens, and discusses the most relevant options for increasing the effectiveness of doripenem in clinical practice, namely, the use of higher doses of antibiotic, the extensive introduction of extended infusion and the use of combination therapy with simultaneous administration of several antimicrobial agents (including two carbapenems).

Full Text

Restricted Access

About the authors

O. U Stetsyuk

Institute of Antimicrobial Chemotherapy FSBEI HE “Smolensk State Medical University" of RMH

Email: olga.stetsiouk@antibiotic.ru
PhD, Senior Researcher

I. V Andreeva

Institute of Antimicrobial Chemotherapy FSBEI HE “Smolensk State Medical University" of RMH

R. S Kozlov

Institute of Antimicrobial Chemotherapy FSBEI HE “Smolensk State Medical University" of RMH

References

  1. Андреева И.В., Стецюк О.У. Дорипенем -новый карбапенем на фармацевтическом рынке России. Фарматека. 2008;20:39-41.
  2. Стецюк О.У., Андреева И.В., Козлов Р.С., Новый карбапенемный антибиотик дорипенем: перспективы применения в клинической практике. Клин. микробиол. антимикроб. химиотер. 2008;10(3):245-59.
  3. Fritsche T.R., Stilwell M.G., Jones R.N. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol, infect. 2005;11(12):974-84.
  4. Mushtaq S., Ge Y., Livermore D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob. Agents Chemother. 2004;48(4):1313-19.
  5. Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю., Иванчик Н.В., Микотина А.В., Дехнич А.В., Козлов Р.С. и исследовательская группа «МАРАФОН». Антибиотикорезистентность нозокомиальных штаммов Enterobacteriaceae в стационарах России: результаты многоцентрового эпидемиологического исследования «МАРАФОН» 2013-2014. Клин. микробиол. антимикроб. химиотер. 2017;19(1):49-56.
  6. Эйдельштейн М.В., Сухорукова М.В., Склеенова Е.Ю., Иванчик Н.В., Микотина А.В., Шек Е.А., Дехнич А.В., Азизов И.С., Козлов Р.С. и исследовательская группа «МАРАФОН». Антибиотикорезистентность нозокомиальных штаммов Pseudomonas aeruginosa в стационарах России: результаты многоцентрового эпидемиологического исследования «МАРАФОН» 2013-2014. Клин. микробиол. антимикроб, химиотер. 2017;19(1):37-41.
  7. Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю., Иванчик Н.В., Шек Е.А., Дехнич А.В., Азизов И.С., Козлов Р.С. и исследовательская группа «МАРАФОН». Антибиотикорезистентность нозокомиальных штаммов Acinetobacter spp. в стационарах России: результаты многоцентрового эпидемиологического исследования «МАРАФОН» 2013-2014. Клин. микробиол. антимикроб. химиотер. 2017;19(1):42-8.
  8. Определение чувствительности микроорганизмов к антимикробным препаратам. Клинические рекомендации. Версия-2015-02. http://www.antibiotic.ru/ minzdrav/files/docs/clrec-dsma2015.pdf
  9. Gales A.C, Azevedo H.D., Cereda R.F., Girardello R., Xavier D.E. INVITA-A-DORI Brazilian Study Group. Antimicrobial activity of doripenem against Gram-negative pathogens: results from iNViTA-A-DORi Brazilian study. Braz. J. infect. Dis. 2011;15(6):513-20.
  10. Jones R.N., Huynh H.K., Biedenbach D.J. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. 2004;48(8):3136-40.
  11. Fera M.T., Zummo S., Dе Sarro A. in vitro activity studies of doripenem and two other carbapenems tested against Pseudomonas aeruginosa and other non-fermentative bacilli. J. Chemother. 2011;23(6):335-40.
  12. Marti S., Sanchez-Cespedes J., Alba V., Vila J. in vitro activity of doripenem against Acinetobacter baumannii clinical isolates. int. J. Antimicrob. Agents. 2009;33:181-82.
  13. Lascols C., Legrand P., Mérens A., Leclercq R., Armand-Lefevre L., Drugeon H.B., Kitzis M.D., Muller-Serieys C., Reverdy M.E., Roussel-Delvallez M., Moubareck C., Lemire A., Miara A., Gjoklaj M., Soussy C.J. in vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints. Eur. J. Clin. Microbiol. infect. Dis. 2011;30:475-82.
  14. Министерство здравоохранения Российской Федерации. Инструкция по применению лекарственного препарата для медицинского применения Дорипрекс® (Doriprex®). https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=7f93e824-3eaa-4d0e-8cf7-ef122f9f2cf4&t=
  15. Kim A., Banevicius M.A., Nicolau D.P. in vivo efficacy of doripenem human-simulated exposures against Pseudomonas aeruginosa. in: Program and abstracts of the 47th iCAAC. American Society for Microbiology, Washington D.C., 2007.
  16. Bhavnani S.M., Hammel J.P., Cirincione B.B., Wikler M.A., Ambrose P.G. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother. 2005;49(9):3944-47.
  17. Mazzei T. The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem. J. Chemother. 2010; 22 (4):219-25.
  18. Thye D., Kilfoil T., Leighton A., Wikler M. Doripenem: A phase 1 study to evaluate safety, tolerability and pharmacokinetics in a western healthy volunteer population. Abstr. A-21. in: Program and Abstracts of the 43rd interscience Conference on Antimicrobial Agents and Chemotherapy (iCAAC); American Society for Microbiology, Washington D.C., 2003.
  19. Floren L.C., Wikler M.A., Kilfoil T., Ge Y. A phase i, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects. in: Program and abstracts of the 44th interscience Conference on Antimicrobial Agents and Chemotherapy (iCAAC); American Society for Microbiology, Washington D.C., 2004.
  20. Nicolau D.P. Carbapenems: a potent class of antibiotics. Expert Opin. Pharmacother. 2008;9(1):23-37.
  21. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin. infect. Dis. 1998;27(1):10-22.
  22. Samtani M.N., Flamm R., Kaniga K., Nandy P. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically illpatients. Antimicrob. Agents Chemother. 2010;54(6):2360-64.
  23. Van Wart S.A., Andes D.R., Ambrose P.G., Bhavnani S.M. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn. Microbiol. infect. Dis. 2009;63(4):409-14.
  24. Kollef M.H., Chastre J., Clavel M., Restrepo M.I., Michiels B., Kaniga K., Cirillo I., Kimko H., Redman R. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit. Care. 2012;16(6):R218.
  25. Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 2008;36 (4):1089-96.
  26. Qu X.Y., Hu T.T., Zhou W. A meta-analysis of efficacy and safety of doripenem for treating bacterial infections. Braz. J. infect. Dis. 2015;19(2):156-62.
  27. Jenkins S.G., Fisher A.C., Peterson J.A., Nicholson S.C., Kaniga K. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase iii efficacy and safety clinical trials. Curr. Med. Res. Opin. 2009;25(12):3029-36.
  28. Chow J.W., Yu V.L. Combination antibiotic therapy versus monotherapy for gram-negative bacteremia: a commentary. int. J. Antimicrob. Agents. 1999;11:7-12.
  29. Urban C., Mariano N., Rahal J.J. in vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother. 2010;54 (6):2732-34.
  30. Zusman O., Avni T., Leibovici L., Adler A., Friberg L., Stergiopoulou T., Carmeli Y., Paul M. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob. Agents Chemother. 2013;57(10):5104-11.
  31. Clock S.A., Tabibi S., Alba L., Kubin C.J., Whittier S., Saiman L. in vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 2013;76(3): 343-46.
  32. Bulik C.C., Nicolau D.P. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2011;55(6):3002-4.
  33. Bulik C.C., Nicolau D.P. In vivo efficacy of human simulated prolonged infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2010;54:4112-15.
  34. Anderson K.F., Lonsway D.R., Rasheed J.K., Biddle J., Jensen B., McDougal L.K., Carey R.B., Thompson A., Stocker S., Limbago B., Patel J.B. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J. Clin. Microbiol. 2007;45(8):2723-25.
  35. Wiskirchen D.E., Nordmann P., Crandon J.L., Nicolau D.P. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 2014;58(3):1671-77.
  36. Wiskirchen D.E., Nordmann P., Crandon J.L., Nicolau D.P. Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model. Antimicrob. Agents Chemother. 2014;58(3):1678-83.
  37. Wiskirchen D.E., Nordmann P., Crandon J.L., Nicolau D.P. Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing Enterobacteriaceae in a murine infection model. Antimicrob. Agents Chemother. 2013;57(8):3936-40.
  38. Wiskirchen D.E., Crandon J.L., Nicolau D.P. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents. 2013;41(6):582-85.
  39. Giamarellou H., Galani L., Baziaka F., Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2013;57(5):2388-90.
  40. Ceccarelli G., Falcone M., Giordano A., Mezzatesta M.L., Caio C., Stefani S., Venditti M. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2013;57(6):2900-901.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies